Börner, Katy http://orcid.org/0000-0002-3321-6137
Teichmann, Sarah A. http://orcid.org/0000-0002-6294-6366
Quardokus, Ellen M.
Gee, James C.
Browne, Kristen
Osumi-Sutherland, David
Herr, Bruce W. II http://orcid.org/0000-0002-6703-7647
Bueckle, Andreas http://orcid.org/0000-0002-8977-498X
Paul, Hrishikesh
Haniffa, Muzlifah http://orcid.org/0000-0002-3927-2084
Jardine, Laura
Bernard, Amy http://orcid.org/0000-0003-2540-1153
Ding, Song-Lin
Miller, Jeremy A.
Lin, Shin
Halushka, Marc K.
Boppana, Avinash
Longacre, Teri A.
Hickey, John
Lin, Yiing
Valerius, M. Todd http://orcid.org/0000-0001-8143-9231
He, Yongqun http://orcid.org/0000-0001-9189-9661
Pryhuber, Gloria
Sun, Xin
Jorgensen, Marda
Radtke, Andrea J. http://orcid.org/0000-0003-4379-8967
Wasserfall, Clive
Ginty, Fiona
Ho, Jonhan
Sunshine, Joel
Beuschel, Rebecca T.
Brusko, Maigan
Lee, Sujin
Malhotra, Rajeev http://orcid.org/0000-0003-0120-4630
Jain, Sanjay
Weber, Griffin
Article History
Received: 30 January 2021
Accepted: 29 September 2021
First Online: 8 November 2021
Competing interests
: In the past 3 years, S.A.T. has received remuneration for consulting and Scientific Advisory Board membership from Genentech, Roche, Biogen, GlaxoSmithKline, Foresite labs, Qiagen and Transition Bio and she is a co-founder and equity holder of Transition Bio. R.M. receives research funding from Bayer and Amgen and serves as a consultant for Myokardia/BMS and Third Pole; he is a co-founder of Patch Inc; he is a co-inventor for a patent no. PCT/US2O12/O22119 on pharmacologic BMP inhibitors (along with Mass General Brigham) for which he receives royalties from Keros Therapeutics, Inc.; he also receives royalties from UpToDate for scientific content authorship. The other authors declare no competing interests.
Free to read: This content has been made available to all.